Objective: To evaluate the safety, feasibility, and tissue response of a novel device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia, using the first-generation Urocross Expander System (Mercury Expander System).
Methods: The implant was deployed and retrieved using flexible cystoscope in 8 adult male canines, separated into three study arms by retrieval date (1-, 6-, and 12- months post-deployment). Cystoscopy and urethrograms verified implant position/diameter; bladder neck and external sphincter function/changes; prostatic tissue response; and implant condition. One-month post-retrieval, the prostate and surrounding tissue was sectioned and evaluated by a veterinary pathologist.
Results: All implants were successfully deployed in the prostatic urethra. Urethral width was increased (6.9 ± 1.8 mm to 10.2 ± 0.6 mm, P = .012) and preserved through the dwell period. Urethral length and sphincter diameters didn't significantly change. All subjects (n = 8) remained continent without obstruction or retention. Adverse events included incisional site bleeding (n = 2) and transient hematuria (n = 3). One implant migrated into the bladder and spontaneously repositioned into the prostatic urethra. Post-retrieval, explant surfaces demonstrated no tissue growth, encrustation or stone formation. Imaging revealed contact site erythema and indentation, but no stones, strictures, perforations, erosions, nor ulcerations. Histopathology revealed glandular acinar changes, inflammation, and fibrosis.
Conclusion: The first generation of the Urocross Expander System demonstrated a favorable safety profile in the canine model. Changes in the prostatic urethra shape were noted with an increase in urethral width during the dwell period with minimal tissue changes. Further, the implant didn't demonstrate any encrustation, tissue growth or stone formation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2021.10.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bladder mucosal smoothness predicts early recovery of urinary continence after laparoscopic radical prostatectomy.
BMC Urol
January 2025
Department of Urology, Peking University Third Hospital, Haidian District, Beijing, 100191, P.R. China.
Background: To propose the bladder mucosal smoothness (BMS) grade and validate a predictive model including MRI parameters preoperatively that can evaluate the early recovery of urinary continence (UC) after laparoscopic radical prostatectomy (LRP).
Methods: A retrospective analysis was conducted on 203 patients (83 patients experienced UI at the three-month follow-up) who underwent LRP in our medical center and were diagnosed with prostate cancer (PCa) from June 2016 to March 2020. Patients' clinicopathological data were collected.
Risk factors of urinary tract infection through demographic and laboratory markers among benign prostate hyperplasia patients: a single-center study.
Folia Med (Plovdiv)
December 2024
Universitas Sumatera Utara, Medan, Indonesia.
Prostate enlargement known as benign prostatic hyperplasia (BPH) increases the risk of infection in the urinary tract by obstructing or blocking the prostatic portion of the urethra. This disease becomes more common as people age.
View Article and Find Full Text PDFCellular cartography reveals mouse prostate organization and determinants of castration resistance.
bioRxiv
December 2024
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109.
Inadequate response to androgen deprivation therapy (ADT) frequently arises in prostate cancer, driven by cellular mechanisms that remain poorly understood. Here, we integrated single-cell RNA sequencing, single-cell multiomics, and spatial transcriptomics to define the transcriptional, epigenetic, and spatial basis of cell identity and castration response in the mouse prostate. Leveraging these data along with a meta-analysis of human prostates and prostate cancer, we identified cellular orthologs and key determinants of ADT response and resistance.
View Article and Find Full Text PDFDosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.
Rep Pract Oncol Radiother
December 2024
Department of Biomedical Physics, Faculty of Physics, Adam Mickiewicz University, Poznań, Poland.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material And Methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market.
Late erosion of an Adjustable Transobturator Male System (ATOMS) device.
IJU Case Rep
January 2025
Department of Urology Bendigo Health Bendigo Victoria Australia.
Introduction: This report describes late erosion of an Adjustable Transobturator Male System device which was inserted for post-prostatectomy incontinence. The Adjustable Transobturator Male System device eroded the bulbar urethra 5 years post insertion, despite initial improvement of symptoms.
Case Presentation: Following an open radical retropubic prostatectomy, a 64 year-old male patient developed post-prostatectomy incontinence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!